

Blood Biomarkers of Uveal Melanoma: Current Perspectives

This article was published in the following Dove Press journal:
Clinical Ophthalmology

Manuel F Bande Rodríguez^{1,2}
Beatriz Fernandez Marta¹
Nerea Lago Baameiro³
Maria Santiago-Varela^{1,2}
Paula Silva-Rodríguez^{2,4}
María Jose Blanco-Teijeiro^{1,2}
Maria Pardo Perez³
Antonio Piñeiro Ces^{1,2}

¹Unidad de Retina Quirúrgica y Tumores Intraoculares del Adulto (URQTIA), Servicio de Oftalmología Xerencia de Xestión Integrada de Santiago de Compostela, SERGAS, Santiago de Compostela, Spain; ²Tumores Intraoculares en el Adulto, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain; ³Grupo Obesidómica, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain; ⁴Fundación Pública Galega de Medicina Xenómica, Clinical University Hospital, SERGAS, Santiago de Compostela 15705, Spain

Abstract: The detection of metastases in patients with a diagnosis of uveal melanoma (UM) is a controversial issue. While only 1% of the patients have detectable metastases at the time of diagnosis, up to 30% of them will develop liver metastases within 5 years of treatment. UM spreads hematogenously, therefore, blood biomarkers may be helpful for prognosis and monitoring the disease progression. Despite the great progress achieved thanks to the genetic analysis of UM biopsies, this is an invasive technique and is limited by the heterogeneity of the tumor. The present review considers the current understanding in the field regarding biomarkers for the diagnosis and prognosis of UM and its metastasis, primarily to the liver. General covered topics include non-conventional markers such as proteins previously identified in cutaneous melanoma and UM cell lines, circulating tumor cells, microRNAs (miRNA), and circulating DNA, and how each may be critical in the development of novel blood biomarkers for UM.

Keywords: uveal melanoma, biomarker, circulating tumor cells, microRNAs, circulating DNA, exosome

Introduction

The detection of metastases in patients with a diagnosis of uveal melanoma (UM) is a controversial issue. Only 1% of the patients show metastases at diagnosis;¹ however, up to 30% of them will develop liver metastases within 5 years of treatment. The most accepted hypothesis explaining this phenomenon is based on the theory of early dissemination and micrometastasis, which are not detected by current screening methods, and may be in a quiescent status until some sort of factor, still unknown, promotes its progression.

Recent studies highlight the importance of cytogenetic characteristics in the prognosis of UM. Thus, chromosome 3 loss is associated with a reduction in the probability of 5-year survival from approximately 100% to 50%.^{2,3} In turn, chromosome 8 gain and 1 loss correlate significantly with poorer survival.^{2,4} Similarly, in recent years, gene expression profiles (GEP) have been used to categorize UMs according to their messenger RNA (mRNA) expression profile. GEPs are used to classify UMs for disease-specific mortality risk with class 1A being very low risk (2% risk at 5 years), class 1B being low risk (21% risk at 5 years), and class 2 being high risk (72% at 5 years).² Unfortunately, these tests require an invasive technique to obtain the tumor samples from either enucleation or intraoperative biopsy by fine needle aspiration (FNA).⁵

In oncology, blood biological markers are used to facilitate diagnosis, establish a prognosis, and predict the therapeutic response of a neoplasm in a non-invasive

Correspondence: Manuel F Bande Rodríguez
Unidad de Retina Quirúrgica y Tumores Intraoculares del Adulto (URQTIA), Servicio de Oftalmología Xerencia de Xestión Integrada de Santiago de Compostela, SERGAS, Santiago de Compostela, Spain
Tel +34981951756
Fax +34981956189
Email verman017@hotmail.com

way. One of the greatest challenges pursued by modern medicine is to predict the risk of suffering a pathological event in a healthy person or a specific patient. Therefore, there is growing interest in the identification of diagnostic and prognostic biomarkers at circulating level. The ideal biomarker and its implementation should be specific, sensitive, predictive, rapid, cost-effective, stable in vivo and in vitro, non-invasive, and of sufficient preclinical and clinical relevance to modify decisions regarding the pathological process in which it is applied.⁶

Currently, imaging methods are often used to clinically detect and monitor cancer metastasis. Because liver metastases are the most common for metastatic UM, abdominal ultrasound and a liver biochemical function test are considered adequate.^{7,8} Hepatic ultrasound is a non-invasive, accessible, and relatively inexpensive method of metastasis screening. This method is used routinely in the initial evaluation of UM patients by European specialists (79%); however, this is not used by North American specialists (3%), they rely primarily upon liver function tests and chest x-rays.⁷ The sensitivity of ultrasound for the detection of UM metastasis ranges from 40% to 89% and its specificity is close to 96%.⁹ Although computed tomography/positron emission tomography (CT/PET) imaging would seem to be the most sensitive, given its very high cost and low availability, its use is impractical. On the other hand, MRI is also superior to CT for detecting UM associated retinal detachments and extra-scleral extensions.¹⁰ Thus, there is no evidence that CT surpasses ultrasound for the early diagnosis of liver metastases. The most established guideline is to perform six-monthly systemic follow-ups (liver ultrasound + liver function test) during the first 5 years and annually thereafter. Systemic monitoring is recommended to be lifelong.¹¹

Conventional Markers: Hepatic Serology

As mentioned above, the liver is involved in most cases of UM metastasis. Currently, liver function tests (LFT), liver ultrasounds, chest radiography, and in some cases, CT is used to follow-up patients treated for UM. According to the Collaborative Ocular Melanoma Study Group (COMS),¹² the LFT should include alanine aminotransferase (ALT), which was formerly known as glutamic-pyruvic transaminase (GPT); aspartate aminotransferase (AST), which was formerly known as glutamic-oxalacetic transaminase (GOT); alkaline phosphatase (FAL); gamma glutamyl transpeptidase

(GGP); lactic dehydrogenase (LDH); and bilirubin. The LFT results are considered abnormal if $AST > 2 \times$ the major normal reference limit (LNR), $ALT > 2$ on LNR, $FAL > 1.5$ on LNR, and bilirubin ≥ 2.0 mg/100 mL.

Different studies have shown that serum levels of liver enzymes increase in the presence of metastasis;^{8,13} however, most of these studies find low sensitivity. For instance, some studies give maximum sensitivity of LFT to ALT (sensitivity, 21%) and alkaline phosphatase (sensitivity, 25%).^{13,14} Others report the highest sensitivity being for LDH at 67%.⁹ Although the sensitivities of each of the enzymes individually are low, Eskelin et al¹⁵ observed that using a panel of enzymes, including ALT, AST, FAL, LDH, and bilirubin, that at least one of those is altered in 70% of the patients who develop metastases. Kaiserman et al¹⁶ obtained similar results in a patient series. They found that 50% of the patients with liver metastases showed an increase in at least one of the enzymes 6 months prior to image diagnosis.

According to COMS,¹² the sensitivity, specificity, positive, and negative predictive value associated with at least one abnormal LFT prior to the first diagnosis of metastasis were 14.7%, 92.3%, 45.7%, and 71.0%, respectively. The values increased to 24.1%, 98.2%, 75.3%, and 85.4% if the time to obtain the results of the analyses was limited to 90 days prior to the diagnosis of metastasis. Table 1 shows the diagnostic properties of each liver enzyme in more detail. Despite limitations in this field of research, determination of circulating levels of these enzymes is used in specialized eye oncology centers.

Non-Conventional Markers: Non-Hepatic Serology

The low sensitivity and specificity of liver enzyme levels and the low positive predictive value greatly encourage the search for new serological markers capable to detect disease progression. This challenge has led researchers to initially focus on serum markers, previously described in cutaneous melanoma, to test its possible application for UM (Table 2). This is the case for the protein S100 β , that was one of the first biomarkers tested in UM, due to its utility for monitoring cutaneous melanoma.¹⁷ Thus, S100 β is a powerful prognostic marker in stages III and IV skin melanomas.¹⁸ The S100 β belongs to a family of low molecular weight proteins present in vertebrates and are characterized by two calcium-binding sites with helix-loop-helix structures (EF-hand).¹⁹ S100 β was first isolated from neurological tissues and as such, it is

Table 1 Diagnostic Properties of Liver Enzymes in Uveal Melanoma Metastatic Disease (UM)

ENZYME	Eskelin et al ⁹					
	Sensitivity (%)		Specificity (%)		Likelihood Ratio (+)	
FAL	27		93		5.0	
AST	43		95		5.8	
ALT	38		90		3.8	
LDH	67		96		14.7	
	COMS Report 23 ⁹ –90 days earlier					
ENZYME	Sensitivity (%)		Specificity (%)		Positive predictive values (%)	
	Large	Medium	Large	Medium	Large	Medium
FAL	18.9	14.4	99.3	99.3	92.3	72.7
AST	10.0	7.1	98.9	99.6	79.2	66.7
ALT	12.8	7.3	98.6	99.4	80.0	61.5
Bilirubin	4.2	0	99.1	99.6	66.7	0
> 1 altered (LFT)	26.7	19.6	97.8	98.5	83.6	61.1

Note: Data from Eskelin et al.⁹

Abbreviations: ALT, alanine-aminotransferase; aspartate-aminotransferase (AST), FAL, alkaline phosphatase; LDH, lactic dehydrogenase; LFT, liver function tests.

Table 2 Cutaneous Melanoma Biomarkers

Study	Marker	No Metastasis		N Number (Metastases)	N Number Control
		N Number (Not)	N number (Treated)		
Missotten et al ²⁴	S-100 β	44 0.04 μ g/L	–	20 0.06 μ g/L	58 0.03 μ g/L
Schaller et al ³⁰	MIA	131 6.6 ng/mL	–	8 26.28 ng/mL	NO
Reiniger et al ³¹	MIA	125 7.27 ng/mL	160 7.43 ng/mL	20 13.03 ng/mL	NO
Haritoglou et al ³⁹	MIA	18 5.64 ng/mL		14 13.11 ng/mL	
	OPN	18 47.39 ng/mL		14 152.01 ng/mL	
Kadkol et al ³⁷	OPN	–	37 7.15 ng/mL	15 17.62 ng/mL	30 6.71 ng/mL
Suesskind et al ⁴⁰	GDF-15	170 1.5 ng/mL		18 10.53 ng/mL	18 1.09 ng/mL
Missotten et al ²⁵	MIA	104 5.63 ng/L	–	30 8.13 ng/L	50 5.18 ng/l
	S-100 β	104 0.07 μ g/L		30 0.23 μ g/L	50 0.06 μ g/L
Barak et al ³⁸	MIA S-100 β OPN	–	38	18	44
Barak et al ⁴¹	MIA S-100 β OPN CK18	–	43	32	53

a sensitive indicator of brain-tissue damage and neurological dysfunction.²⁰ It is present in the retina where it participates in the signaling pathways between photoreceptors and Müller cells.²¹ Additionally, high levels of S100 β are detected in vitreous and aqueous humor.²² Cochran et al were the first to demonstrate the presence of S100 β in histological slices of choroidal melanoma. However, subsequent studies have shown that the tissue expression of S100 β is less relevant in other tissues compared to that in cutaneous melanoma.²³ In addition, serum concentration of S100 β lacks a predictive value and does not correlate with other prognostic factors in UM.^{24,25}

Melanoma inhibitory activity (MIA) protein was discovered in cutaneous melanoma cell cultures and identified for its ability to inhibit the incorporation of thymidine by melanoma cell lines.²⁶ Subsequently, MIA has been found to be specifically expressed in cutaneous melanoma cells, chondrocytes, and in an advanced breast cancer subgroup.²⁷ MIA specifically inhibits the binding of melanoma cells to fibronectin and laminin, and therefore is suspected to regulate the detachment of melanoma cells from the extracellular matrix, which is an important step in the metastatic cascade.²⁸ Moreover, it has been shown that there is a good correlation between the stage of the skin tumor and the concentration of MIA protein in the blood.²⁹ Shaller and collaborators³⁰ noted that MIA is expressed in primary and metastatic UM lesions, and reported a statistically significant elevation of serum MIA levels in patients who develop metastases. On the contrary, Reiniger and other authors demonstrated, in a cohort of 305 UM patients, that serum MIA concentration does not reach enough value as a predictive marker, and therefore it is not useful to estimate the risk of developing metastatic disease.³¹ Under the above, it is important to note that although progression of UM cannot be excluded in those patients with normal serum MIA levels, abnormal levels of MIA may indicate a probable presence of metastatic disease.³¹

Another protein of interest is osteopontin (OPN), which is a phosphoprotein capable of binding to calcium, with high affinity for hydroxyapatite playing an important role in bone mineralization and dystrophic calcification.³² This protein has been described in the context of various physiological functions, including chemotaxis, cell migration, cell adhesion, angiogenesis, apoptosis, extracellular cell-matrix interactions, immune regulation, and tumor metastasis.³³ Thus, it was shown that osteopontin actively promotes a tumorigenic phenotype and contributes to metastasis.³⁴ Increased osteopontin expression is associated with aggressive behavior and

metastasis in breast, colon, prostate, lung, liver, and ovarian cancers. Moreover, a soluble form of this protein is secreted into the blood showing a positive correlation with advanced or metastatic stage cancers.³⁵ The discovery that cutaneous melanoma cells with invasive behavior express more osteopontin at tissue level³⁶ led to the study of this marker in the context of UM. Various studies have shown that osteopontin is diffusely expressed in tissue sections of UM liver metastases and that serum levels of osteopontin correlate with melanoma metastases in the liver with significant specificity and sensitivity.^{37,38}

Growth Differentiation Factor 15 (GDF-15/MIC-1) is a divergent member of the TGF- β superfamily. Members of this family are important regulators of cellular physiological processes, including cell survival, proliferation, differentiation, migration, and apoptosis.⁴² GDF-15 is highly expressed in many melanoma cell lines compared to that in normal human melanocytes, and is also overexpressed in biopsy specimens of metastatic cutaneous melanoma.⁴³ It is therefore hypothesized to have melanoma promoting properties. Patients with clinically detectable metastases have significantly higher serum GDF-15 levels compared to those without clinically detectable metastases, as well as to healthy individuals.⁴⁰ Interestingly, paralleling skin melanoma, concentrations of GDF-15 are higher in patients with clinically detectable UM metastases compared to those UM patients that are in remission or those without clinically detected UM metastases.⁴⁰

Liver Biomarkers

Metastasis is a highly selective and complex process that includes the proliferation and growth of tumor cells in the parenchyma of target organs to complete the metastatic process requiring the formation of new blood vessels (angiogenesis).⁴⁴ Thus, it is assumed that the interactions between tumor cells and the microenvironments of the target organ are the primary determinants in the outcome of the metastatic process.⁴⁵ The fact that the liver is the main target organ in UM metastasis raises the suspicion that growth factors synthesized in the liver, such as hepatocyte growth factor (HGF), epidermal growth factor (EGF), insulin growth factor type 1 (IGF-1), and their receptors, may play a role in the acceptance and survival of the metastatic UM cells.⁴⁶ Hendrix and other authors found that hepatocyte growth factor receptor (HGFR/c-Met) expression correlates with the invasive capacity of UM cell lines.⁴⁷ On the other hand, a close and positive correlation has been described among the immunoreactivity of

the EGF receptor (EGFR) in UM tissue, the progression to metastasis, and a decrease in survival.⁴⁸

Among the growth factors synthesized by the liver, special attention is paid to IGF-1 since it is the only growth factor that has been studied in the serum of patients with UM.⁴⁹ IGF-1 is a soluble protein produced by the liver that binds to a transmembrane receptor called IGF-1R. This receptor is expressed throughout the body, but primarily in cartilage, bone, liver, kidneys, lung, and the central nervous system.⁵⁰ IGF-1R plays an important role in the cell cycle, anaerobic respiration, pediatric growth, and aging. IGF-1R is also important in the development of metastatic tumors, cell proliferation, and the prevention of apoptosis.⁵¹ Unlike other markers, serum IGF-1 levels tend to decrease in patients who develop UM metastasis.⁵²

In recent years, studies have been published that describe a possible relationship between Vascular Endothelial Growth Factor (VEGF) levels in serum of patients with UM and the risk of developing metastasis. Boyd et al and later Missotten et al showed that VEGF concentrations increase in eye aqueous humor in association with UM.^{53,54} While determining the amount of VEGF in the serum of patients with UM, it has been observed that the levels are not elevated at the time of enucleation and that only those patients with metastases have a high concentration of VEGF in their serum.⁵⁵ A recent study by Barak and collaborators presented similar confirming results. Therefore, although no correlation has been found between VEGF expression by the primary tumor and histologic parameters, VEGF levels are significantly higher in patients with metastatic disease when they value themselves interpersonally before and after metastasis.⁵⁶ An increase in VEGF on serial measurements could indicate the development of UM metastases.

Other Biomarkers

There are other biological factors expressed by most malignant tumors, including UM, that can be measured in serum. These include factors associated with tumor angiogenesis (basic FGF or IL-8),⁵⁷ adhesion (ICAM and VCAM),⁵⁸ and invasion (matrix metalloproteinases 1 and 9).⁵⁹

Patients with eosinophilia show a trend towards longer survival in various types of cancer, including melanoma. Recently, elevated serum concentrations of cationic eosinophil protein (ECP) were indicated to increase survival of patients with UM.⁶⁰

It is worth mentioning the carcinoembryonic antigen (CEACAM-1), which was first described in UM by Michelson and other authors.⁶¹ These researchers

demonstrated an increase of CEA in the sera of patients with UM metastasis. However, the inconvenience with this marker is that it may also be increased in other types of tumors (eg, ovarian and colon cancer).⁶²

Finally, we mention the recent work of Song and collaborators who evaluated different serum biomarkers using a multiple immunoassay based on magnetic microspheres. They were selected after a literature search and with an in silico analysis of gene and protein databases reported to be useful for the detection of UM. To OPN, MIA, CEACAM-1, MIC-1 were added proteins related to the progression of cutaneous melanoma (periostin/POSTN)⁶³ and others whose increase was associated with poor prognosis in other types of cancer (Heat shock protein 27/HSP27 and Spondin 1/SPON1).^{64,65} Multivariate analysis identified HSP27 and OPN as the best combination of markers to discriminate UM patients from healthy controls. The combination of MIA and MIC-1 was also useful in differentiating between patients with metastatic and disease-free UM, although this was not statistically significant due to the small sample size.⁶⁶

Proteins Identified from UM Cells Cultured in vitro

A comprehensive study of the proteome of the primary UM cell culture UM-A was the first of its kind in the literature and represents an important first step towards the use of proteomic technology in the study of UM tumor cells.⁶⁷ A total of 683 proteins derived from 393 different genes were identified. Of these 683 proteins, 18% were related to carcinogenic processes by their association with cell proliferation, invasion, metastasis, oncogenesis, and drug resistance.

The expression of some of these new identified proteins was validated by immunodetection in UM-A cells and other UM cell lines established by other groups, including UW-1, OCM-1, SP6.5, and 92.1. These proteins include MUC18 (MelCAM/CD146) and high mobility group protein (HMG-1). The expression of MUC18 has been associated with increased metastatic potential in other neoplasms, such as prostate and bladder cancer.⁶⁸ Our work shows for the first time the relationship between MUC18 and in vitro invasion of UM. On the other hand, HMG-1 intervenes in the transcriptional regulation of genes that play a key role in different biological processes of neoplastic progression and metastasis.⁶⁹ Subsequently, the analysis of secreted proteins (secretomes) of the mentioned UM cell lines was also characterized, finding proteins relevant to the development of cancer, such as cathepsin D, PMEL/ME20M, DJ-1/PARK7,

and syntenin 1. Interestingly, DJ-1, ME20M, and cathepsin D were detected in the sera of patients with UM at higher levels compared to those of healthy individuals.^{70,71} The reference studies performed by our group and those of others using UM cell lines are listed in **Box 1**.

The pro-oncogenic characteristic of DJ-1 was first described regarding its ability to transform NIH-3T3 cells when expressed alone or in combination with other oncogenes, such as c-Myc or H-Ras.⁷⁷ DJ-1 appears to regulate several cellular signaling pathways that are related to survival. Thus, DJ-1 modulates the PI3K/Akt pathway by inactivating PTEN.⁷⁸ Apart from regulating this pathway, DJ-1 also interacts with other genes such as Von Hippel Lindau (VHL), which is a tumor suppressor gene involved in the ubiquitination and degradation of the factor inducible by hypoxia (HIF-1a) under normoxia.⁷⁹ On the other hand, several studies have shown a link between p53 and DJ-1 of which some suggest an anti-apoptotic function of DJ-1 through the repression of the transcriptional activity of p53. DJ-1 may interfere with the binding of p53 to promoter DNA in order to suppress the transcription of the proapoptotic factor Bax, thereby inhibiting caspase activation.⁸⁰

Our group has demonstrated that DJ-1 presents significantly higher serum concentrations in patients with choroidal nevi that has manifested some risk factors for malignancy.⁸¹ The risk factors include symptoms at the time of diagnosis of UM, acoustic shadow on ultrasound, nevus height > 1.5 mm, and a basal diameter > 8 mm.⁸² The mean serum level of this group of patients was 89.56 ng/mL compared to 37.39 ng/mL for the nevus group without associated risk factors and 32.98

ng/mL for the control group.⁸³ This indicates that DJ-1 could be a potential marker of malignant transformation of choroid nevi. On the other hand, Chen et al have related DJ-1 to the presence of UM metastases. In their study, they observed a sensitivity and specificity of DJ-1 circulating levels with metastasis detection of 74.1% and 94.3%, respectively.⁸⁴

In contrast to DJ-1, PMEL/ME20M is a melanocyte-specific protein. ME20M plays a central role in the biogenesis of melanosomes.⁸⁵ It participates in the ripening of stage I and stage II melanosomes. The release of a soluble form of this protein ME20-S/M-alpha may protect tumor cells from antibody-mediated immunity.⁸⁶ We found significantly higher concentrations of ME20-S in patients in the UM untreated group and in patients with liver metastases than in the choroid nevus or control group. **Figure 1**.⁸⁷ In addition, it is important to note that patients with UM treated without metastasis had protein concentrations similar to those in the control group.⁸⁷ Regarding the analysis of the effects of height and base on levels of ME20-S in patients with untreated choroidal nevus or UM, positive associations were found between serum levels of ME20-S and height of melanocytic lesion.⁸⁷ Thus, we conclude, that PMEL(ME20-S) might be a promising serum marker for UM and useful for monitoring metastatic disease.

In summary, osteopontin (OPN), calcium-binding protein B S100 (S-100B), cytokine-1 inhibitor of macrophages (MIC-1), and Parkinsonian protein (DJ-1/PARK7) appear to have higher serum concentration in metastatic UM patients. However, these proteins are not specific to melanoma and may undergo wide interindividual variability as in the case of VEGF. Although the combination of serum markers (eg, OPN, MIA, and S100B) provides a more sensitive method for detecting metastases than LFT liver metastases, these studies are of few patients and their use has not yet been adopted in universal clinical practice. We advocate large multicenter studies with specific melanoma biomarkers (MIA and ME20-S) and sequential measurement of levels of these proteins in patient sera.

Circulating Tumor Cells

Circulating tumor cells (CTCs) were first described in 1869 by Thomas Ashworth,⁸⁸ describing them as “tumor-like cells that can be seen in blood.” However, it was not until 1990 that research regarding CTCs and their association with oncology in the clinic began.⁸⁹ To date, the confirmation and enumeration of CTCs have been accomplished using flow cytometry techniques, direct cytometry

Box 1 Summary of Proteomics Studies in Tumors and Uveal Melanoma (UM) Cell Lines

Pardo et al ⁶⁷	Global UM cell line proteome (UM-A)
Pardo et al ⁷¹	Differential proteome of UM cell lines (less and more aggressive)
Pardo et al ⁷⁰	Global secretome proteome of 5 UM cell lines
Zuidervaat et al ⁷²	Differential cell line proteome derived from a primary tumor and metastasis
Wang et al ⁷³	Differential proteome of irradiated UM cell lines.
Yan et al ⁷⁴	Differential proteome of irradiated UM cell lines.
Angi et al ⁷⁵	Comparative analysis of high and low risk tumors of metastasis.
Surman et al ⁷⁶	Proteome derived from ectosomes secreted uveal melanoma cells




Figure 1 Logarithmic scale representation of serum ME20-S levels in five groups of patients (Control, Choroidal Nevi, Untreated UM, 10-year disease-free (DFUM), hepatic metastatic UM). Significance level: *** $p < 0.001$. Adapted from Bande MF, Santiago M, Mera P, et al. ME20-S as a potential biomarker for the evaluation of uveal melanoma. *Invest Ophthalmol Vis Sci*. 2015;56(12):7007–7011. Copyright 2015 The Association for Research in Vision and Ophthalmology, Inc.⁸⁷

analysis, fluorescent in situ hybridization, and polymerase chain reaction (PCR) analysis of RNA and DNA of tumor cells. The identification of CTCs in the blood is becoming an important clinical tool, even though CTCs are rarely seen in cancer patients; however, it is estimated that there is one CTC for every mononuclear cell.⁹⁰

In the specific case of UM, the presence of CTCs in the blood of patients was described as early as 1969 using standard microscopic techniques and staining with orange acridine nuclear dye.⁹¹ Over the years, techniques used for patients with cutaneous melanoma have been applied in patients with UM.⁹² The most frequently used method for the detection of CTCs in patients with UM has been PCR. Tyrosinase mRNA was able to be detected in blood samples from three out of six patients diagnosed with UM.⁹³ Two of the patients who were positive for tyrosinase mRNA had metastatic disease with the third initially being non-metastatic, but who did develop metastases nine months later. Based on these results, the investigators studied a larger cohort of 36 patients with UM.⁹⁴ Contrary to expectations, CTCs were not detected using tyrosinase

PCR in any of the 51 blood samples they collected and analyzed. Blood samples were also taken before and after primary treatment in 41 patients with UM with no metastatic disease being detectable at the time of diagnosis.⁹⁵ Treatment was based on clinical indications and included enucleation, brachytherapy, or transpupillary thermotherapy. Patients were followed up for the development of metastases or for a minimum period of 5 years. At the start of the study, 16 of the 41 patients tested positive for CTCs. A total of 11 of these 16 patients (69%) were negative for CTCs after treatment of the primary tumor. Although a positive correlation was found between the presence of CTCs and the probability of metastasis at 5 years, there was no correlation between the positivity of CTCs and clinical risk factors, such as tumor size, histology, or treatment method.

On the other hand, Callejo et al published an important finding using multi-marker PCR that allows the simultaneous detection of several molecular markers.⁹⁰ They studied 30 patients with UM, 5 at the time of initial diagnosis and the other 25 at various times after diagnosis and initial

treatment, ranging from 1 to 17 years. PCR was used to detect tyrosinase and MART-1 mRNA expression. They collected an average of four blood samples per patient; one at the time of the initial visit and subsequent samples at 3-month intervals. They detected CTCs in 29 of the 30 patients in more than 119 visits. However, no correlation was found between the presence of CTCs and tumor size, type of treatment, or time since treatment. The authors attributed their differing results compared to those of previous studies to their use of a more sensitive approach involving the use of more blood samples (four versus one or two), the collection of large amounts of blood (30 mL versus 5–15 mL), a larger number of PCRs (20 versus one), and to their inclusion of more than one marker. Despite this argument, mRNA analysis is known to be susceptible to false positives due to “illegitimate” transcription or contamination.⁹⁶

To overcome these limitations, immunomagnetic classification particles with anti-melanoma antibodies, which recognized human high molecular weight-melanoma-associated antigen (HMW-MAA), have been used. Ulmer and collaborators were the first to suggest this approach for patients with UM.⁹⁷ These investigators examined the blood of 52 patients with non-metastatic UM and identified CTCs in 19% of the samples (1–5 cells/50 mL), with a positive relationship established to clinical prognostic factors (ciliary body invasion, advanced local tumor stage, and anterior tumor localization). Likewise, Suesskind and other authors found 14% of the peripheral blood samples from 81 patients with UM to be positive for CTCs but found no correlation with clinical parameters.⁹⁸ In a study carried out by Mazzini et al, the malignant cells were isolated by filtration in a cohort of 31 UM patients. By stratifying patients into groups based on the number of CTCs (less than or greater than 10 CTCs per 10 mL of blood) and the presence of CTC groups, a significant difference was found in LBD, tumor height, disease-free survival, and overall survival ($p < 0.05$).⁹⁹

A similar study by our group assessed the level of peripheral blood CTC in patients with nevus and non-metastatic choroidal melanoma. No CTC was found in patients with choroidal nevus, while at least one CTC/7.5mL was found in 50% of the patients with UM. The highest number of CTCs was recorded in the patient with the largest choroidal melanoma, which presented extra-scleral extension and epithelial pathology. However, no significant relationship was found between the positivity of CTC and the clinical-pathological parameters of the lesions (basal diameter of the tumor and height of the tumor).⁸³

Our results above were corroborated by another recent article, conducted by Bidard and collaborators. In this work, the CTC count and DNA levels of tumor cells were associated with the presence of miliary liver metastases and with the volume of metastases. CTC was correlated and both have poor prognostic significance.¹⁰⁰

In a study conducted by Terai et al, it was found that CTCs are detectable more frequently and in greater numbers in arterial blood samples compared to that of venous samples in UM.¹⁰¹ Patients with UM liver metastases and extrahepatic metastases show a higher number of arterial CTCs compared to patients with liver metastases alone. There is no significant association between the number of arterial CTCs and the tumor load in the liver in patients with liver metastases.

Taken together, the data obtained to date from the different studies using CTCs of UM have been inconsistent. This is probably caused by variations in test procedures. Thus, further work is necessary to reconcile these differences.

MicroRNA

MicroRNAs (miRNAs) are a family of small non-coding RNAs that regulate a wide range of biological processes including carcinogenesis. In cancer cells, miRNAs have been found to be heavily dysregulated. The functional characterization of miRNAs, especially their interaction with oncogenes, tumor suppressor genes, and other cancer-related genes may help us to better understand the tumorigenesis process.¹⁰² Several studies have been conducted on UM using miRNA expression tests. Therefore, expression of certain miRNAs (let-7b, miR-199a, miR-199a, miR-143, miR-193b, and miR-652) was associated with chromosome 3 status, gene expression profile classes, and prognosis.¹⁰³

In a study by Nannan Liu and collaborators using UM cell lines with higher and lower invasive potential, it was shown that MiR-9 is involved in the regulation of the NF- κ B pathway.⁷⁷ MiR-9 expression is reduced in melanoma cells with high invasive capacity. This reduced expression appears to negatively modulate the expression of NF- κ B1, thereby suppressing cell migration and invasive capacity that is regulated by the NF- κ B1 signaling pathway. Meanwhile, Chen et al studied the expression of miR-124a in UM cell lines using RT-PCR. They determined that miR-124a expression is down-regulated in UM cells. They found that miR-124a inhibits the functions of CDK4, CDK6, cyclin D2, and EZH2, which results in inhibition of migration and invasion of UM cells.¹⁰⁹

Achberger and collaborators were the first to study miRNA in the sera of patients with UM. They extracted blood from six patients with UM at the time of diagnosis that did not have clinical or radiographic evidence of metastasis. Plasma and cell levels of miRNA were determined using quantitative PCR (qPCR) assays. Plasma levels of miR-20a, 125b, 146a, 155, 181a, and 223 were all higher in the patients at the time of diagnosis compared with that of controls. Plasma levels of miR-20a, 125b, 146a, 155 and 223 increased and miR-181a levels decreased when metastasis manifested.¹⁰⁴

The results of the miRNA studies involving UM are summarized in Table 3. However, after completion of all these works, it is clear that only a small number of miRNAs were common among the different studies and several miRNAs even exhibit discordant patterns of expression among them. These discrepancies are possibly due to quality differences in the clinical samples, the different classification and inclusion criteria used in each study, sample processing variations, previous cytotoxic treatments, tumor heterogeneity, and underestimation of hypoxia and infection. It is therefore important to re-evaluate the current strategies used in miRNA profiles and to be cautious with respect to interpreting the existing data.¹⁰⁵

Circulating DNA

The mechanism of DNA release into the bloodstream is not completely clear. It has been suggested that the presence of high levels of ctDNA in the blood of patients with tumors is caused by apoptosis and the necrosis of tumor cells or by the release of intact cells into the bloodstream and their subsequent lysis.¹¹⁰

Circulating DNA is the genetic material that releases all cells – both healthy and tumor cells. This ctDNA reflects at the molecular level the characteristics of the cells of origin. For this reason, its analysis in a blood sample makes it possible to obtain molecular information on the tumor being studied. In addition, ctDNA reflects the mutations present throughout the tumor, not just in a sample of the tumor obtained by biopsy. More than 80% of the UMs present with mutations in the proto-oncogenes GNAQ and GNA11.^{5,111} For that reason, PCR techniques for ctDNA of UM patients include screening for GNAQ c.626A>T, GNAQ c.626A>C, and GNA11 c.626A>T.¹⁰⁰

In a cohort study conducted by Bidard et al,⁸⁴ ctDNA was detected in 84% of the patients with metastatic UM. The detection of ctDNA correlates with the presence of liver metastases, tumor size, and CTCs. ctDNA levels are strongly associated with progression-free survival and overall survival.¹⁰⁰ In patients with detectable mutations, ctDNA is detected more frequently than CTCs and therefore appears to have a higher prognostic value. Both CTCs and ctDNA were associated with miliary liver metastases. These small perivascular metastatic foci within the liver are the result of hematogenous spread, which may explain the increased detection of CTCs and the increased release of ctDNA into the bloodstream.¹⁰⁰

Conclusions and Future Prospects

Genetic biopsy methods for UM have a number of limitations: (1) concern that the biopsy may spread tumor cells leading to a poorer prognosis of survival, (2) concern that

Table 3 Summary of microRNA (miRNA) Studies Involved in Uveal Melanoma (UM) Detection

	Type of Sample	miRNA Overexpressed in Metastatic UM	miRNA Overexpressed in Non-Metastatic UM	miRNA Under-Expressed in Metastatic UM
Worley et al ¹⁰³	Histological	let-7b, miR-199a, miR-199a*, miR-143, miR-193b and miR-652		
Liu et al ¹⁰⁶	Cell lines			miR9
Radhakrishnan et al ¹⁰⁷	Histological	miR-196a, miR-549, miR-497, miR-885-5p, miR-585, miR-640, miR-512-5p, miR-556-5p, miR-135b, miR-325, miR-99a, miR-33a	miR-495, miR-18a, miR-586, miR-493, miR-377, miR-376c, miR-369-3p, miR-34c-5p, miR-26a-2, miR-218, miR-19b-1, miR-154, miR-181a, miR-133a, miR-129, miR10a, miR1, Let-7e	
Yang and Wei ¹⁰⁸	Histological	miRNA-20a, miRNA-106a, miRNA-17, miRNA-21 and miRNA-34a		miRNA-145 and miRNA-204
Chen et al ¹⁰⁹	Cell lines			miR-124a
Achberger et al ¹⁰⁴	Serum	miR-20a, 125b, 146a, 155 and 223		miR-181a

the biopsy will worsen the visual prognosis of the eye (14.3% experienced intravitreal hemorrhage),¹¹² (3) the belief that FNA may lead to misdiagnosis due to sampling failures, and (4) the lack of conviction that cytopathologic analyses of FNA biopsy specimens can effectively distinguish between tumors with low-risk and high-risk for metastasis due to tumor heterogeneity.¹¹³ In addition, it is important to note that both methods (GEP and MLPA) are only prognostic, not diagnostic. For these reasons, it is important to identify other non-invasive biomarkers that will allow the detection and diagnosis of UM at different stages of disease and tumorigenesis.

The use of appropriate blood biomarkers in clinical practice with periodic monitoring of their levels would allow health-care providers to guide the management of patients with UM, to establish therapy protocols, and to directly evaluate the progress or control of the disease. The combination of using these biomarkers, in combination with the tests currently established during routine check-ups, would represent a great advancement in the decision-making process and in the clinical approach for treating these patients.

Moreover, new molecular players such as extracellular vesicles including exosomes have emerged into play lately. Exosomes are vesicles from 30 to 150 nm derived from cells containing various proteins, nucleic acids, and lipids. These vesicles facilitate intercellular communication and cause micro-environmental changes. Interest in exosomes as specific and accurate biomarkers has intensified dramatically in recent years due to their ability to transport a variety of molecular components from the cells of origin.¹¹⁴ Exosomes released by tumor cells have also been shown to play a very active role in tumorigenesis, metastasis, and response to therapy through the transfer of oncogenes and onco-miRNAs between cancer cells and the tumor stroma.¹¹⁵ Exosomes in target organs trigger the necessary molecular responses for inflammation and vascularization to host CTCs.

In the future, the quantitation of CTCs and their subsequent genetic analysis may allow for the replacement of primary tumor biopsy with simple blood collection. The ctDNA is found in the blood of patients with advanced cancer and may be used as a source of biological material to determine the somatic genetic characteristics of these tumors. Detection of the gene mutation in ctDNA could also be very useful for prognostic classification of UMs as it is in other types of cancer.^{116,117}

The diagnostic approach to UM using serum markers would avoid or delay the use of other more aggressive diagnostic methods such as tumor biopsy. However, some

studies show differing results. The unification of the criteria for inclusion and processing of samples promises more reliable results in the future.

Disclosure

The authors report no conflicts of interest in this work.

References

- Zimmerman LE, McLean IW, Foster WD. Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells. *Br J Ophthalmol*. 1978;62(6):420–425. doi:10.1136/bjo.62.6.420
- Damato B, Duke C, Coupland SE, et al. Cytogenetics of uveal melanoma: a 7-year clinical experience. *Ophthalmology*. 2007;114(10):1925–1931. doi:10.1016/j.ophtha.2007.06.012
- Shields CL, Ganguly A, Materin MA, et al. Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases. *Trans Am Ophthalmol Soc*. 2007;105:43–52; discussion 52–43.
- Damato B, Dopierala JA, Coupland SE. Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. *Clin Cancer Res*. 2010;16(24):6083–6092. doi:10.1158/1078-0432.CCR-10-2076
- Field MG, Harbour JW. Recent developments in prognostic and predictive testing in uveal melanoma. *Curr Opin Ophthalmol*. 2014;25(3):234–239. doi:10.1097/ICU.0000000000000051
- Strimbu K, Tavel JA. What are biomarkers? *Curr Opin HIV AIDS*. 2010;5(6):463–466. doi:10.1097/COH.0b013e32833ed177
- Gombos DS, Van Quill KR, Uusitalo M, O'Brien JM. Geographic disparities in diagnostic screening for metastatic uveal melanoma. *Ophthalmology*. 2004;111(12):2254–2258. doi:10.1016/j.ophtha.2004.06.022
- Donoso LA, Berd D, Augsburger JJ, Mastrangelo MJ, Shields JA. Metastatic uveal melanoma. Pretherapy serum liver enzyme and liver scan abnormalities. *Arch Ophthalmol*. 1985;103(6):796–798. doi:10.1001/archoph.1985.01050060056024
- Eskelin S, Pyrhonen S, Summanen P, Prause JU, Kivela T. Screening for metastatic malignant melanoma of the uvea revisited. *Cancer*. 1999;85(5):1151–1159. doi:10.1002/(SICI)1097-0142(19990301)85:5<1151::AID-CNCR20>3.0.CO;2-G
- Mafee MF. Uveal melanoma, choroidal hemangioma, and simulating lesions. Role of MR imaging. *Radiol Clin North Am*. 1998;36(6):1083–1099, x. doi:10.1016/S0033-8389(05)70233-5
- Damato B. Developments in the management of uveal melanoma. *Clin Experiment Ophthalmol*. 2004;32(6):639–647. doi:10.1111/ceo.2004.32.issue-6
- Diener-West M, Reynolds SM, Agugliaro DJ, et al. Screening for metastasis from choroidal melanoma: the collaborative ocular melanoma study group report 23. *J Clin Oncol*. 2004;22(12):2438–2444. doi:10.1200/JCO.2004.08.194
- Einhorn LH, Burgess MA, Gottlieb JA. Metastatic patterns of choroidal melanoma. *Cancer*. 1974;34(4):1001–1004. doi:10.1002/(ISSN)1097-0142
- Hicks C, Foss AJ, Hungerford JL. Predictive power of screening tests for metastasis in uveal melanoma. *Eye*. 1998;12(Pt 6):945–948. doi:10.1038/eye.1998.245
- Eskelin S, Pyrhonen S, Summanen P, Hahka-Kemppinen M, Kivela T. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. *Ophthalmology*. 2000;107(8):1443–1449. doi:10.1016/S0161-6420(00)00182-2

16. Kaiserman I, Amer R, Pe'er J. Liver function tests in metastatic uveal melanoma. *Am J Ophthalmol.* 2004;137(2):236–243. doi:10.1016/j.ajo.2003.08.045
17. Wollina U, Karte K, Hipler UC, Knoll B, Kirsch K, Herold C. Serum protein s100beta in patients with malignant melanoma detected by an immunoluminometric assay. *J Cancer Res Clin Oncol.* 2000;126(2):107–110. doi:10.1007/s004320050018
18. Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmuller D. Clinical significance of serum S100 in metastatic malignant melanoma. *Eur J Cancer.* 1995;31A(11):1898–1902. doi:10.1016/0959-8049(95)00087-Y
19. Moore BW. A soluble protein characteristic of the nervous system. *Biochem Biophys Res Commun.* 1965;19(6):739–744. doi:10.1016/0006-291X(65)90320-7
20. Shi S, Wang G, Zhang K, et al. Expression of S100beta protein in patients with vascular dementia after basal ganglia hemorrhage and its clinical significance. *Exp Ther Med.* 2017;13(5):1917–1921. doi:10.3892/etm.2017.4207
21. Nomura-Komoiike K, Saitoh F, Komoiike Y, Fujieda H. DNA damage response in proliferating muller glia in the mammalian retina. *Invest Ophthalmol Vis Sci.* 2016;57(3):1169–1182. doi:10.1167/iovs.15-18101
22. Cochran AJ, Holland GN, Saxton RE, et al. Detection and quantification of S-100 protein in ocular tissues and fluids from patients with intraocular melanoma. *Br J Ophthalmol.* 1988;72(11):874–879. doi:10.1136/bjo.72.11.874
23. Cochran AJ, Holland GN, Wen DR, et al. Detection of cytoplasmic S-100 protein in primary and metastatic intraocular melanomas. *Invest Ophthalmol Vis Sci.* 1983;24(8):1153–1155.
24. Missotten GS, Tang NE, Korse CM, et al. Prognostic value of S-100-beta serum concentration in patients with uveal melanoma. *Arch Ophthalmol.* 2003;121(8):1117–1119. doi:10.1001/archophth.121.8.1117
25. Missotten GS, Korse CM, van Dehn C, et al. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests. *Tumour Biol.* 2007;28(2):63–69. doi:10.1159/000099151
26. Blesch A, Bosserhoff AK, Apfel R, et al. Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. *Cancer Res.* 1994;54(21):5695–5701.
27. Bosserhoff AK, Moser M, Hein R, Landthaler M, Buettner R. In situ expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers. *J Pathol.* 1999;187(4):446–454. doi:10.1002/(SICI)1096-9896(199903)187:4<446::AID-PATH267>3.0.CO;2-Y
28. Bosserhoff AK, Buettner R. Expression, function and clinical relevance of MIA (melanoma inhibitory activity). *Histol Histopathol.* 2002;17(1):289–300. doi:10.14670/HH-17.289
29. Bosserhoff AK, Lederer M, Kaufmann M, et al. MIA, a novel serum marker for progression of malignant melanoma. *Anticancer Res.* 1999;19(4A):2691–2693.
30. Schaller UC, Bosserhoff AK, Neubauer AS, Buettner R, Kampik A, Mueller AJ. Melanoma inhibitory activity: a novel serum marker for uveal melanoma. *Melanoma Res.* 2002;12(6):593–599. doi:10.1097/00008390-200212000-00009
31. Reiniger IW, Schaller UC, Haritoglou C, et al. “Melanoma inhibitory activity” (MIA): a promising serological tumour marker in metastatic uveal melanoma. *Graefes Arch Clin Exp Ophthalmol.* 2005;243(11):1161–1166. doi:10.1007/s00417-005-1171-4
32. Steitz SA, Speer MY, McKee MD, et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. *Am J Pathol.* 2002;161(6):2035–2046. doi:10.1016/S0002-9440(10)64482-3
33. Zhao H, Chen Q, Alam A, et al. The role of osteopontin in the progression of solid organ tumour. *Cell Death Dis.* 2018;9(3):356. doi:10.1038/s41419-018-0391-6
34. Zhou Y, Dai DL, Martinka M, et al. Osteopontin expression correlates with melanoma invasion. *J Invest Dermatol.* 2005;124(5):1044–1052. doi:10.1111/j.0022-202X.2005.23680.x
35. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. *Br J Cancer.* 2004;90(10):1877–1881. doi:10.1038/sj.bjc.6601839
36. Denhardt D. Osteopontin expression correlates with melanoma invasion. *J Invest Dermatol.* 2005;124(5):xvi–xviii. doi:10.1111/j.0022-202X.2005.23708.x
37. Kadkol SS, Lin AY, Barak V, et al. Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study. *Invest Ophthalmol Vis Sci.* 2006;47(3):802–806. doi:10.1167/iovs.05-0422
38. Barak V, Frenkel S, Kalickman I, Maniotis AJ, Folberg R, Pe'er J. Serum markers to detect metastatic uveal melanoma. *Anticancer Res.* 2007;27(4A):1897–1900.
39. Haritoglou I, Wolf A, Maier T, Haritoglou C, Hein R, Schaller UC. Osteopontin and ‘melanoma inhibitory activity’: comparison of two serological tumor markers in metastatic uveal melanoma patients. *Ophthalmologica.* 2009;223(4):239–243. doi:10.1159/000206139
40. Suesskind D, Schatz A, Schnichels S, et al. GDF-15: a novel serum marker for metastases in uveal melanoma patients. *Graefes Arch Clin Exp Ophthalmol.* 2012;250(6):887–895. doi:10.1007/s00417-011-1786-6
41. Barak V, Kaiserman I, Frenkel S, Hendler K, Kalickman I, Pe'er J. The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1). *Anticancer Res.* 2011;31(1):345–349.
42. Bootcov MR, Bauskin AR, Valenzuela SM, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. *Proc Natl Acad Sci U S A.* 1997;94(21):11514–11519. doi:10.1073/pnas.94.21.11514
43. Boyle GM, Pedley J, Martyn AC, et al. Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity. *J Invest Dermatol.* 2009;129(2):383–391. doi:10.1038/jid.2008.270
44. Amaro A, Gangemi R, Piaggio F, et al. The biology of uveal melanoma. *Cancer Metastasis Rev.* 2017;36(1):109–140.
45. Langley RR, Fidler IJ. Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. *Endocr Rev.* 2007;28(3):297–321.
46. Kivela T, Eskelin S, Kujala E. Metastatic uveal melanoma. *Int Ophthalmol Clin.* 2006;46(1):133–149. doi:10.1097/01.iio.0000195861.71558.13
47. Hendrix MJ, Seftor EA, Seftor RE, et al. Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/scatter factor (HGF/SF). *Am J Pathol.* 1998;152(4):855–863.
48. Seftor EA, Meltzer PS, Kirschmann DA, et al. Molecular determinants of human uveal melanoma invasion and metastasis. *Clin Exp Metastasis.* 2002;19(3):233–246. doi:10.1023/A:1015591624171
49. Frenkel S, Zloto O, Pe'er J, Barak V. Insulin-like growth factor-1 as a predictive biomarker for metastatic uveal melanoma in humans. *Invest Ophthalmol Vis Sci.* 2013;54(1):490–493. doi:10.1167/iovs.12-10228
50. Bondy CA, Werner H, Roberts CT Jr., LeRoith D. Cellular pattern of insulin-like growth factor-I (IGF-I) and type I IGF receptor gene expression in early organogenesis: comparison with IGF-II gene expression. *Mol Endocrinol.* 1990;4(9):1386–1398. doi:10.1210/mend-4-9-1386
51. Pollak MN. Insulin-like growth factors and neoplasia. *Novartis Found Symp.* 2004;262:84–98;discussion 98–107, 265–108.
52. Al-Jamal RT, Kivela T. Prognostic associations of insulin-like growth factor-1 receptor in primary uveal melanoma. *Can J Ophthalmol.* 2011;46(6):471–476. doi:10.1016/j.cjco.2011.09.013

53. Boyd SR, Tan D, Bunce C, et al. Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. *Br J Ophthalmol*. 2002;86(4):448–452. doi:10.1136/bjo.86.4.448
54. Missotten GS, Notting IC, Schlingemann RO, et al. Vascular endothelial growth factor in eyes with uveal melanoma. *Arch Ophthalmol*. 2006;124(10):1428–1434. doi:10.1001/archophth.124.10.1428
55. El Filali M, GS M, Maat W, et al. Regulation of VEGF-A in uveal melanoma. *Invest Ophthalmol Vis Sci*. 2010;51(5):2329–2337. doi:10.1167/iovs.09-4739
56. Barak V, Pe'er J, Kalickman I, Frenkel S. VEGF as a biomarker for metastatic uveal melanoma in humans. *Curr Eye Res*. 2011;36(4):386–390. doi:10.3109/02713683.2010.534573
57. Ijland SA, Jager MJ, Heijdra BM, Westphal JR, Peek R. Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines. *Melanoma Res*. 1999;9(5):445–450. doi:10.1097/00008390-199910000-00003
58. Anastassiou G, Schilling H, Stang A, Djakovic S, Heiligenhaus A, Bornfeld N. Expression of the cell adhesion molecules ICAM-1, VCAM-1 and NCAM in uveal melanoma: a clinicopathological study. *Oncology*. 2000;58(1):83–88. doi:10.1159/000012083
59. Lai K, Conway RM, Crouch R, Jager MJ, Madigan MC. Expression and distribution of MMPs and TIMPs in human uveal melanoma. *Exp Eye Res*. 2008;86(6):936–941. doi:10.1016/j.exer.2008.03.010
60. Kruckel A, Moreira A, Frohlich W, Schuler G, Heinzerling L. Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma. *BMC Cancer*. 2019;19(1):207. doi:10.1186/s12885-019-5384-z
61. Michelson JB, Felberg NT, Shields JA. Carcinoembryonic antigen. Its role in the evaluation of intraocular malignant tumors. *Arch Ophthalmol*. 1976;94(3):414–416. doi:10.1001/archophth.1976.03910030200005
62. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. *JAMA*. 1993;270(8):943–947. doi:10.1001/jama.1993.03510080047030
63. Kudo Y, Siriwardena BS, Hatano H, Ogawa I, Takata T. Periostin: novel diagnostic and therapeutic target for cancer. *Histol Histopathol*. 2007;22(10):1167–1174. doi:10.14670/HH-22.1167
64. Vidyasagar A, Wilson NA, Djamali A. Heat shock protein 27 (HSP27): biomarker of disease and therapeutic target. *Fibrogenesis Tissue Repair*. 2012;5(1):7. doi:10.1186/1755-1536-5-7
65. Pyle-Chenault RA, Stolk JA, Moles DA, et al. VSGP/F-spondin: a new ovarian cancer marker. *Tumour Biol*. 2005;26(5):245–257. doi:10.1159/000087379
66. Song J, Merbs SL, Sokoll LJ, Chan DW, Zhang Z. A multiplex immunoassay of serum biomarkers for the detection of uveal melanoma. *Clin Proteomics*. 2019;16:10. doi:10.1186/s12014-019-9230-8
67. Pardo M, Garcia A, Thomas B, et al. Proteome analysis of a human uveal melanoma primary cell culture by 2-DE and MS. *Proteomics*. 2005;5(18):4980–4993. doi:10.1002/pmic.200500030
68. Wu GJ, Wu MW, Wang SW, et al. Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression. *Gene*. 2001;279(1):17–31. doi:10.1016/S0378-1119(01)00736-3
69. Reeves R, Edberg DD, Li Y. Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. *Mol Cell Biol*. 2001;21(2):575–594. doi:10.1128/MCB.21.2.575-594.2001
70. Pardo M, Garcia A, Antrobus R, Blanco MJ, Dwek RA, Zitzmann N. Biomarker discovery from uveal melanoma secretomes: identification of gp100 and cathepsin D in patient serum. *J Proteome Res*. 2007;6(7):2802–2811. doi:10.1021/pr070021t
71. Pardo M, Garcia A, Thomas B, et al. The characterization of the invasion phenotype of uveal melanoma tumour cells shows the presence of MUC18 and HMG-1 metastasis markers and leads to the identification of DJ-1 as a potential serum biomarker. *Int J Cancer*. 2006;119(5):1014–1022. doi:10.1002/ijc.21942
72. Zuidervaart W, Hensbergen PJ, Wong MC, et al. Proteomic analysis of uveal melanoma reveals novel potential markers involved in tumor progression. *Invest Ophthalmol Vis Sci*. 2006;47(3):786–793. doi:10.1167/iovs.05-0314
73. Wang F, Bing Z, Zhang Y, et al. Quantitative proteomic analysis for radiation-induced cell cycle suspension in 92-1 melanoma cell line. *J Radiat Res*. 2013;54(4):649–662. doi:10.1093/jrr/trt010
74. Yan LB, Shi K, Bing ZT, Sun YL, Shen Y. Proteomic analysis of energy metabolism and signal transduction in irradiated melanoma cells. *Int J Ophthalmol*. 2013;6(3):286–294. doi:10.3980/j.issn.2222-3959.2013.03.06
75. Angi M, Kalirai H, Prendergast S, et al. In-depth proteomic profiling of the uveal melanoma secretome. *Oncotarget*. 2016;7(31):49623–49635. doi:10.18632/oncotarget.v7i31
76. Surman M, Hoja-Lukowicz D, Szwed S, et al. An insight into the proteome of uveal melanoma-derived ectosomes reveals the presence of potentially useful biomarkers. *Int J Mol Sci*. 2019;20:15. doi:10.3390/ijms20153789
77. Nagakubo D, Taira T, Kitaura H, et al. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. *Biochem Biophys Res Commun*. 1997;231(2):509–513. doi:10.1006/bbrc.1997.6132
78. Wilson MA. The role of cysteine oxidation in DJ-1 function and dysfunction. *Antioxid Redox Signal*. 2011;15(1):111–122. doi:10.1089/ars.2010.3481
79. Vasseur S, Afzal S, Tardivel-Lacombe J, Park DS, Iovanna JL, Mak TW. DJ-1/PARK7 is an important mediator of hypoxia-induced cellular responses. *Proc Natl Acad Sci U S A*. 2009;106(4):1111–1116. doi:10.1073/pnas.0812745106
80. Fan J, Ren H, Jia N, et al. DJ-1 decreases bax expression through repressing p53 transcriptional activity. *J Biol Chem*. 2008;283(7):4022–4030. doi:10.1074/jbc.M707176200
81. Bande MF, Santiago M, Blanco MJ, et al. Serum DJ-1/PARK 7 is a potential biomarker of choroidal nevi transformation. *Invest Ophthalmol Vis Sci*. 2012;53(1):62–67. doi:10.1167/iovs.11-7948
82. Pineiro-Ces A, Rodriguez Alvarez MJ, Santiago M, et al. Detecting ultrasonographic hollowness in small choroidal melanocytic tumors using 10 MHz and 20 MHz ultrasonography: a comparative study. *Graefes Arch Clin Exp Ophthalmol*. 2014;252(12):2005–2011. doi:10.1007/s00417-014-2758-4
83. Bande MF, Santiago M, Muinelo-Romay L, et al. Detection of circulating melanoma cells in choroidal melanocytic lesions. *BMC Res Notes*. 2015;8:452. doi:10.1186/s13104-015-1420-5
84. Chen LL, Tian JJ, Su L, et al. DJ-1: a promising marker in metastatic uveal melanoma. *J Cancer Res Clin Oncol*. 2015;141(2):315–321. doi:10.1007/s00432-014-1804-2
85. Berson JF, Harper DC, Tenza D, Raposo G, Marks MS. Pmel17 initiates premelanosome morphogenesis within multivesicular bodies. *Mol Biol Cell*. 2001;12(11):3451–3464. doi:10.1091/mbc.12.11.3451
86. Hoashi T, Tamaki K, Hearing VJ. The secreted form of a melanocyte membrane-bound glycoprotein (Pmel17/gp100) is released by ectodomain shedding. *FASEB J*. 2010;24(3):916–930. doi:10.1096/fj.09-140921
87. Bande MF, Santiago M, Mera P, et al. ME20-S as a potential biomarker for the evaluation of uveal melanoma. *Invest Ophthalmol Vis Sci*. 2015;56(12):7007–7011. doi:10.1167/iovs.15-17183
88. Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. *Aust Med J*. 1869;14:146.

89. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. *Lancet*. 1991;338(8777):1227–1229. doi:10.1016/0140-6736(91)92100-G
90. Callejo SA, Anteck E, Blanco PL, Edelstein C, Burnier MN Jr. Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A Prospective Longitudinal Study. *Eye*. 2007;21(6):752–759.
91. Horodenski J. [Studies on the presence of free cells of malignant melanoma of the uvea in peripheral blood]. *Klin Oczna*. 1969;39(3):407–412.
92. Fernandes BF, Belfort RN, Di Cesare S, Burnier MN Jr. Circulating uveal melanoma cells: should we test for them?. *Can J Ophthalmol*. 2008;43(2):155–158. doi:10.3129/i08-011
93. Tobal K, Sherman LS, Foss AJ, Lightman SL. Detection of melanocytes from uveal melanoma in peripheral blood using the polymerase chain reaction. *Invest Ophthalmol Vis Sci*. 1993;34(9):2622–2625.
94. Foss AJ, Guille MJ, Occlleston NL, Hykin PG, Hungerford JL, Lightman S. The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. *Br J Cancer*. 1995;72(1):155–159. doi:10.1038/bjc.1995.293
95. Boldin I, Langmann G, Richtig E, et al. Five-year results of prognostic value of tyrosinase in peripheral blood of uveal melanoma patients. *Melanoma Res*. 2005;15(6):503–507. doi:10.1097/00008390-200512000-00004
96. Mocellin S, Hoon D, Ambrosi A, Nitti D, Rossi CR. The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. *Clin Cancer Res*. 2006;12(15):4605–4613. doi:10.1158/1078-0432.CCR-06-0823
97. Ulmer A, Beutel J, Susskind D, et al. Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma. *Clin Cancer Res*. 2008;14(14):4469–4474. doi:10.1158/1078-0432.CCR-08-0012
98. Susskind D, Ulmer A, Schiebel U, et al. Circulating melanoma cells in peripheral blood of patients with uveal melanoma before and after different therapies and association with prognostic parameters: a pilot study. *Acta Ophthalmol (Copenh)*. 2011;89(1):17–24. doi:10.1111/j.1755-3768.2009.01617.x
99. Mazzini C, Pinzani P, Salvianti F, et al. Circulating tumor cells detection and counting in uveal melanomas by a filtration-based method. *Cancers*. 2014;6(1):323–332. doi:10.3390/cancers6010323
100. Bidard FC, Madic J, Mariani P, et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. *Int J Cancer*. 2014;134(5):1207–1213. doi:10.1002/ijc.28436
101. Terai M, Mu Z, Eschelman DJ, et al. Arterial blood, rather than venous blood, is a better source for circulating melanoma cells. *EBioMedicine*. 2015;2(11):1821–1826. doi:10.1016/j.ebiom.2015.09.019
102. Peng Y, Croce CM. The role of MicroRNAs in human cancer. *Signal Transduct Target Ther*. 2016;1:15004. doi:10.1038/sigtrans.2015.4
103. Worley LA, Long MD, Onken MD, Harbour JW. Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. *Melanoma Res*. 2008;18(3):184–190. doi:10.1097/CMR.0b013e3282feeac6
104. Achberger S, Aldrich W, Tubbs R, Crabb JW, Singh AD, Triozzi PL. Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease. *Mol Immunol*. 2014;58(2):182–186. doi:10.1016/j.molimm.2013.11.018
105. Li Z, Yu X, Shen J, Jiang Y. MicroRNA dysregulation in uveal melanoma: a new player enters the game. *Oncotarget*. 2015;6(7):4562–4568. doi:10.18632/oncotarget.2923
106. Liu N, Sun Q, Chen J, et al. MicroRNA-9 suppresses uveal melanoma cell migration and invasion through the NF-kappaB1 pathway. *Oncol Rep*. 2012;28(3):961–968. doi:10.3892/or.2012.1905
107. Radhakrishnan A, Badhrinarayanan N, Biswas J, Krishnakumar S. Analysis of chromosomal aberration (1, 3, and 8) and association of microRNAs in uveal melanoma. *Mol Vis*. 2009;15:2146–2154.
108. Yang C, Wei W. The miRNA expression profile of the uveal melanoma. *Sci China Life Sci*. 2011;54(4):351–358. doi:10.1007/s11427-011-4149-y
109. Chen X, He D, Dong XD, et al. MicroRNA-124a is epigenetically regulated and acts as a tumor suppressor by controlling multiple targets in uveal melanoma. *Invest Ophthalmol Vis Sci*. 2013;54(3):2248–2256. doi:10.1167/iovs.12-10977
110. Rothwell DG, Smith N, Morris D, et al. Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample. *Mol Oncol*. 2016;10(4):566–574. doi:10.1016/j.molonc.2015.11.006
111. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. *Nature*. 2009;457(7229):599–602. doi:10.1038/nature07586
112. Sellam A, Desjardins L, Barnhill R, et al. Fine needle aspiration biopsy in uveal melanoma: technique, complications, and outcomes. *Am J Ophthalmol*. 2016;162:28–34 e21. doi:10.1016/j.ajo.2015.11.005
113. Chang MY, Rao NP, Burgess BL, Johnson L, McCannel TA. Heterogeneity of monosomy 3 in fine needle aspiration biopsy of choroidal melanoma. *Mol Vis*. 2013;19:1892–1900.
114. Wu M, Wang G, Hu W, Yao Y, Yu XF. Emerging roles and therapeutic value of exosomes in cancer metastasis. *Mol Cancer*. 2019;18(1):53. doi:10.1186/s12943-019-0964-8
115. Kharaziha P, Ceder S, Li Q, Panaretakis T. Tumor cell-derived exosomes: a message in a bottle. *Biochim Biophys Acta*. 2012;1826(1):103–111. doi:10.1016/j.bbcan.2012.03.006
116. Bennett CW, Berchem G, Kim YJ, El-Khoury V. Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer. *Oncotarget*. 2016;7(43):71013–71035. doi:10.18632/oncotarget.v7i43
117. Salvianti F, Massi D, De Giorgi V, Gori A, Pazzagli M, Pinzani P. Evaluation of the liquid biopsy for the detection of brafv600e mutation in metastatic melanoma patients. *Cancer Biomark*. Epub 2019 Sep 3.

Clinical Ophthalmology

Publish your work in this journal

Clinical Ophthalmology is an international, peer-reviewed journal covering all subspecialties within ophthalmology. Key topics include: Optometry; Visual science; Pharmacology and drug therapy in eye diseases; Basic Sciences; Primary and Secondary eye care; Patient Safety and Quality of Care Improvements. This journal is indexed on PubMed

Submit your manuscript here: <https://www.dovepress.com/clinical-ophthalmology-journal>

Dovepress

Central and CAS, and is the official journal of The Society of Clinical Ophthalmology (SCO). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.